# To Evaluate the Efficacy and Safety of Gefitinib in Adjuvant Chemotherapy for Lung Adenocarcinoma

> **NCT03656393** · PHASE3 · UNKNOWN · sponsor: **Shenzhen People's Hospital** · enrollment: 48 (estimated)

## Conditions studied

- NSCLC
- EGFR

## Interventions

- **DRUG:** Gefitinib
- **DRUG:** Vinorelbine
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT03656393
- **Lead sponsor:** Shenzhen People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-08-31
- **Primary completion:** 2020-07-31
- **Final completion:** 2020-09-30
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2018-09-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03656393

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03656393, "To Evaluate the Efficacy and Safety of Gefitinib in Adjuvant Chemotherapy for Lung Adenocarcinoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03656393. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*